The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.

Johnson & Johnson reports 73% PSA response in Phase 1 prostate cancer regimen

Nov 8, 2026 16:00 (11h ago)

Verifying

Johnson & Johnson reported Phase 1 results for pasritamig combined with JNJ-9401 in prostate cancer.
Eleven of 15 patients achieved PSA reductions of at least 50% at the recommended regimen.
The combination is being evaluated in the Phase 3 KLK2-comPAS study for mCRPC.